Monopar Therapeutics Inc. (MNPR)
| Market Cap | 350.45M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -17.31M |
| Shares Out | 6.17M |
| EPS (ttm) | -3.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 76,445 |
| Open | 55.70 |
| Previous Close | 54.49 |
| Day's Range | 54.80 - 58.94 |
| 52-Week Range | 3.65 - 58.77 |
| Beta | 1.22 |
| Analysts | Strong Buy |
| Price Target | 68.60 (+20.78%) |
| Earnings Date | Nov 7, 2025 |
About MNPR
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirco... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for MNPR stock is "Strong Buy." The 12-month stock price target is $68.6, which is an increase of 20.78% from the latest price.
News
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments fo...
Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent
Monopar Therapeutics Inc. is a clinical-stage biotech with two promising programs: ALXN1840 for Wilson disease and a radiopharmaceuticals pipeline targeting advanced cancers. ALXN1840 has shown superi...
Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
WILMETTE, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative tr...
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
WILMETTE, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative tre...
Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
WILMETTE, Ill. and HOUSTON, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “us” and “our”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company foc...
Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
WILMETTE, Ill., June 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative tre...
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments
WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative ...
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025
WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unme...
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025
WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with un...
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments
WILMETTE, Ill., March 31, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with un...
Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics
Monopar's pipeline includes clinical-stage radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease NORTH CHICAGO, Ill. , Jan. 23, 2025 /PRNewswire...
Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways
MNPR-101-Lu is being developed in a phase 1 study to target advanced solid tumor patients with uPAR expression. MNPR-101-Zr is being used as an imaging agent to determine which advanced solid tumor pa...
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatme...
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet m...
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet m...
Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus
Monopar Therapeutics is a clinical-stage biotech focused on radiopharmaceuticals for oncology and recently expanded into rare diseases with ALXN-1840. MNPR's oncology pipeline includes MNPR-101-Zr for...
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare Disease Two Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid Ca...
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
WILMETTE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innov...
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innov...
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innov...
Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?
The stock price of Monopar Therapeutics (NASDAQ: MNPR), a clinical-stage biopharmaceutical company, skyrocketed from levels of $5.25 on Monday, October 21, to $32.66 on Thursday, October 24, before fa...
Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder
Monopar Therapeutics Inc. MNPR stock is skyrocketing on Thursday.
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
WILMETTE, Ill., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients...
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
WILMETTE, Ill., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today ...
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today...